The first guideline of PROSTATE CANCER UK states, “In the future, health professionals should look at a man’s PSA level alongside other known risk factors as part of a risk assessment tool, when one becomes available.”93 However, the vast majority of the current PCa risk prediction models are not suitable for routine use as they include clinical and genetic tests and are not validated externally in other cohorts. This evidence concerns the gene KLK3 and posterior cortical atrophy.